Jahnson S, Karlsson M G
Department of Urology, Orebro Medical Centre, Sweden.
J Urol. 1998 Oct;160(4):1291-6.
We elucidate the association between altered immunostaining for retinoblastoma gene protein (pRb) and p53 nuclear proteins, and cancer specific death in patients treated with cystectomy for locally advanced bladder cancer.
The hospital records of 173 patients treated with cystectomy for advanced urothelial bladder cancer between 1967 and 1992 were retrospectively reviewed. Representative biopsies obtained before treatment were sectioned and stained using the standard immunohistochemical technique with antibody DO-7 (p53) and antibody PMG3-245 (pRb). A tumor was considered to have an altered p53 expression if 20% or more of tumor cells exhibited nuclear staining. Similarly, if no tumor cell had nuclear immunostaining the tumor was considered to have an altered pRb expression.
An altered expression was observed for p53 in 98 tumors (57%) and for pRb in 60 (35%). In a proportional hazards analysis no association was found between an altered expression of pRb or p53 and cancer specific death. This finding was also true in another analysis when the results of immunostaining for pRb and p53 were combined.
An altered expression for pRb and/or p53 was not correlated to cancer specific death. Thus, these parameters could not be used as predictors of treatment outcome after cystectomy for locally advanced bladder cancer.
我们阐明视网膜母细胞瘤基因蛋白（pRb）和p53核蛋白免疫染色改变与接受膀胱全切术治疗的局部晚期膀胱癌患者癌症特异性死亡之间的关联。
回顾性分析1967年至1992年间173例接受膀胱全切术治疗的晚期尿路上皮膀胱癌患者的医院记录。治疗前获取的代表性活检组织切片，采用标准免疫组织化学技术，使用抗体DO-7（p53）和抗体PMG3-245（pRb）进行染色。如果20%或更多的肿瘤细胞出现核染色，则认为肿瘤的p53表达改变。同样，如果没有肿瘤细胞核免疫染色，则认为肿瘤的pRb表达改变。
98例肿瘤（57%）中观察到p53表达改变，60例（35%）中观察到pRb表达改变。在比例风险分析中，未发现pRb或p53表达改变与癌症特异性死亡之间存在关联。当将pRb和p53免疫染色结果合并进行另一项分析时，这一发现同样成立。
pRb和/或p53表达改变与癌症特异性死亡无关。因此，这些参数不能用作局部晚期膀胱癌膀胱全切术后治疗结果的预测指标。
